LS
Lisata Therapeutics, Inc.
LSTA · NASDAQ
$1.70 -0.58% (-$0.01)
1M +9.68%
Market Cap $15.8M
P/E Ratio -
Div. Yield -
ROE 113.79%
Piotroski F-Score Weak
1/9Valuation
45 /100
Fair P/S 158.45x
P/B 1.92x
P/E N/A
Growth
0 /100
Declining Book val. growth 39.35%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 95.00%
Net margin 14,621.00%
Op. margin 16,427.00%
Quality
0 /100
Poor ROIC 199.05%
ROE 113.79%
ROA 132.59%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 3.69x
Int. coverage N/A
Stability
61 /100
Moderate Beta 0.80x
EPS volatility 36.23%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LSTA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David J. Mazzo
Employees
21
Headquarters
Basking Ridge
Upcoming events
05 NOV
Earnings
Upcoming earnings report